Fundraising Fox

Abk Biomedical Inc

Halifax, CA · Nova Scotia, Canada corporation · 3 known investors

abkbiomedical.com ↗

ABK Biomedical is a clinical-stage medical device company developing imageable microsphere products for treating cancer, including Eye90 microspheres for Y90 radioembolization in liver cancer and Easi-Vue embolic microspheres for embolization of arteriovenous malformations and hypervascular tumors. Its products are aimed at interventional oncology and radioembolization procedures.

BiotechHealthtechMedical Devices@ABKBiomedical

Founders & leadership

AH
Anthony HeadleyExecutive Officer
GD
Gary DonofrioExecutive Officer
MM
Michael ManganoExecutive Officer, Director
DD
David DobrowskyExecutive Officer
KP
Keten PatelDirector
LB
Lucy BataneantExecutive Officer
JS
Joseph SilettoDirector
MG
Marc GregoireExecutive Officer
CB
Carissa Bellardine BlackDirector
AB
Aaron BerezDirector
JE
James EadieDirector
MT
Mike TysonExecutive Officer

Investors · 3

Eight Roads VenturesBangalore · $5M – $30M
F-Prime Capital PartnersCambridge · $3M – $10M
Vivo CapitalreportedPalo Alto · $10M – $50Mvia Joseph Siletto · board

Reported raises · per SEC filings

Form D private placements
▶$2.6MraisedNov 2025 · 6 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Lucy BataneantExecutive Officer
  • Aravind ArepallyExecutive Officer
  • David DobrowskyExecutive Officer
  • Joseph SilettoDirector
  • James McLarenDirector
  • Marc GregoireExecutive Officer
  • Aaron BerezDirector
  • Keten PatelDirector
  • Anthony HeadleyExecutive Officer
  • Carissa Bellardine BlackDirector
  • Mike TysonExecutive Officer
  • James EadieDirector
  • Gary DonofrioExecutive Officer
  • Michael ManganoExecutive Officer, Director
Offering amount
$2.6M
Amount sold
$2.6M
First sale
Oct 2025
Incorporated
Corporation, Nova Scotia, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$26.1MraisedMay 2025 · 24 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Anthony HeadleyExecutive Officer
  • Gary DonofrioExecutive Officer
  • Michael ManganoExecutive Officer, Director
  • David DobrowskyExecutive Officer
  • Keten PatelDirector
  • Lucy BataneantExecutive Officer
  • Joseph SilettoDirector
  • Marc GregoireExecutive Officer
  • Carissa Bellardine BlackDirector
  • Aaron BerezDirector
  • James EadieDirector
  • Mike TysonExecutive Officer
  • James McLarenDirector
  • Aravind ArepallyExecutive Officer
Offering amount
$26.1M
Amount sold
$26.1M
First sale
Apr 2025
Incorporated
Corporation, Nova Scotia, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$28.5MraisedDec 2022 · 23 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Anthony HeadleyExecutive Officer
  • Ketan PatelDirector
  • Marc GregoireExecutive Officer
  • Aravind ArepallyExecutive Officer
  • Michael ManganoExecutive Officer, Director
  • David DobrowskiExecutive Officer
  • Aaron BerezDirector
  • James McLarenDirector
  • Mike TysonExecutive Officer
  • Gary DonofrioExecutive Officer
  • Carissa BlackDirector
Offering amount
$28.5M
Amount sold
$28.5M
First sale
Dec 2022
Incorporated
Corporation, Nova Scotia, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$23.5MraisedApr 2019 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • James McLarenDirector
  • Michael TysonExecutive Officer
  • David DobrowskiExecutive Officer
  • Robert OrrDirector
  • Aaron BerezDirector
  • Bob AbrahamExecutive Officer, Director
  • Marc GregoireExecutive Officer
  • Michael ManganoExecutive Officer, Director
  • Gary DonofrioExecutive Officer
Offering amount
$23.5M
Amount sold
$23.5M
First sale
Apr 2019
Incorporated
Corporation, Nova Scotia, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.